english.prescrire.org > Topics > Advancing healthcare policy > Prescrire's response to the public consultation on the revision of European pharmaceuticals legislation (12/2021)
Advancing healthcare policy

Via its policy advocacy, Prescrire acts as a force for change in health policies, first and foremost in the interest of patients.
 

Français

Prescrire's response to the public consultation on the revision of European pharmaceuticals legislation (December 2021)

In its response, Prescrire stressed the need for robust evidence before marketing authorisation is granted. Accelerated assessments should be limited to real unmet health needs, with due attention paid to whether post-marketing commitments are fulfilled. To ensure safety of supply, there is a need for diversification of supply chains and transparency over production sites and capacity. Read on...
 


Paris, 15 December 2021


In its response, Prescrire stressed the need for robust evidence before marketing authorisation is granted. Accelerated assessments should be limited to real unmet health needs, with due attention paid to whether post-marketing commitments are fulfilled. To ensure safety of supply, there is a need for diversification of supply chains and transparency over production sites and capacity.

> Click here to download Prescrire's contribution (pdf, 145 Ko)


©Prescrire December 2021
 

Share Share on Facebook Share on Twitter